Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- International Price Comparisons for Neurology Drugs
- Overview
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Reimbursement Environment
- United States
- General Environment
- Cost-Containment Measures
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- France
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Germany
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Italy
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Spain
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- United Kingdom
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Japan
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Outlook and Implications for the Pharmaceutical Industry
- Healthcare Reform in the United States
- Increasing Cost-Containment Pressures
- Pricing Constraints
- Prescribing Restrictions
- Greater Use of Generics and Biosimilars
- Health Technology Assessment
- Innovative Approaches to Pricing and Reimbursement
- Key Messages for Payers
Tables
- 1. Leading Neurology Drugs
- 2. Ex-Manufacturer Prices of Select Neurology Drugs in Europe and Japan as
a Percentage of U.S. Prices, 2008
- 3. Coverage of Select Neurology Drugs by Leading U.S. Private Insurers and
Pharmacy Benefi t Management Companies
- 4. U.S. Managed Care Organizations' Use of Select Cost-Containment
Measures to Control the Use of Biologic Multiple Sclerosis Therapies
- 5. Assessment of Select Neurology Drugs by France' s Transparency Commission
- 6. Timetable for Generics Competition for Leading Neurology Drugs
- 7. Proposed Topics for U.S. Comparative Effectiveness Research Related to
Neurology Drugs
Figures
- 1. Average Ex-Manufacturer Prices of Neurology Drugs as a Percentage of
U.S. Prices, 2008
- 2. Average Ex-Manufacturer Prices of Alzheimer' s Disease Therapies as a
Percentage of U.S. Prices, 2008
- 3. Average Ex-Manufacturer Prices of Parkinson' s Disease Therapies as a
Percentage of U.S. Prices, 2008
- 4. Average Ex-Manufacturer Prices of Multiple Sclerosis Therapies as a
Percentage of U.S. Prices, 2008
- 5. Average Ex-Manufacturer Prices of Antiepileptics as a Percentage of
U.S. Prices, 2008
- 6. Average Ex-Manufacturer Prices of Migraine Therapies as a Percentage of
U.S. Prices, 2008
- 7. Health Insurance Coverage of the Total U.S. Population, 1997-2007
- 8. U.S. Residents' Sources of Prescription Drug Benefi ts, July 2008
- 9. Sources of Healthcare Funding for U.S. Residents by Neurological
Disease, 2008
- 10. Impact of Antiepileptic Switching on U.S. Patients
- 11. Average German Retail Prices of Reference-Priced Neurology Drugs as a
Percentage of Their Respective Reference Prices, 2009
- 12. Copayment-Exempt Neurology Drugs in Germany by Compound, July 2009
- 13. U.S. Managed Care Organizations' Likelihood of Using Step-Therapy
Protocols or Prior Authorization to Promote the Use of Biosimilar
Interferon-Beta-1b
- 14. U.S., French, and German Neurologists' Anticipated Rates of Adoption
for Biosimilar Interferon-Betas
|
Related Report
|
View Cart
